14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
MLTX vs IMTX: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, MoonLake Immunotherapeutics Class A (MLTX) captures the overall head-to-head institutional edge over Immatics N.V. (IMTX) on higher Unified Composite conviction (38.3/100 SELL vs. 49.7/100 HOLD) after splitting the core matrix 3–4 (led by Profitability & Quality, Options & Positioning), while IMTX wins 3–2 across the 6-pillar growth and valuation breakdown. MLTX trades at $11.85 (N/M Forward P/E, 0.0% operating margin) versus IMTX at $6.21 (N/M Forward P/E, -577.1% operating margin).
Composite vs. Pillar Nuance: While IMTX currently prints a higher short-term Unified Composite Score (49.7/100 HOLD vs. MLTX 38.3/100 SELL), MLTX captures the overall institutional head-to-head verdict (3–4 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -577.1% operating margin) and revenue trajectory (+0.0% vs. +33.5% YoY).
Technical & Structure Timing Caution: MLTX is currently in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 49.5); meanwhile IMTX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 33.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MLTX vs IMTX. Trailing 12-month operating profitability (MLTX 0.0% vs IMTX -577.1%) and valuation multiples (MLTX N/M vs IMTX N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $992.8M market capitalization and -577.1% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ MLTX vs IMTX Key Questions & Quantitative Answers
As of Nov 16, 2026, MoonLake Immunotherapeutics Class A (MLTX) captures the overall head-to-head institutional edge over Immatics N.V. (IMTX) on higher Unified Composite conviction (38.3/100 SELL vs. 49.7/100 HOLD) after splitting the core matrix 3–4 (led by Profitability & Quality, Options & Positioning), while IMTX wins 3–2 across the 6-pillar growth and valuation breakdown. MLTX trades at $11.85 (N/M Forward P/E, 0.0% operating margin) versus IMTX at $6.21 (N/M Forward P/E, -577.1% operating margin). Composite vs. Pillar Nuance: While IMTX currently prints a higher short-term Unified Composite Score (49.7/100 HOLD vs. MLTX 38.3/100 SELL), MLTX captures the overall institutional head-to-head verdict (3–4 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -577.1% operating margin) and revenue trajectory (+0.0% vs. +33.5% YoY). Technical & Structure Timing Caution: MLTX is currently in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 49.5); meanwhile IMTX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 33.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
IMTX leads the Growth & Scale pillar: MLTX posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with IMTX at +33.5% YoY revenue growth and +0.0% YoY earnings growth on $43M TTM revenue (N/A gross margin, -577.1% operating margin). On trailing 12-month operating scale, MLTX generates N/A in USD-normalized revenue versus $43M for IMTX. In operating R&D and SG&A reinvestment, MLTX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for IMTX.
IMTX screens cheaper on headline valuation multiples. MLTX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas IMTX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 16.8x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MLTX (-81.5% ROE) versus IMTX (-54.3% ROE) capital efficiency.
In options market volatility and institutional positioning, MLTX carries 111.8% implied volatility (7th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.61β · 90% Vol realized risk). By comparison, IMTX carries 279.5% implied volatility (84th %ile, Extreme (>80th %ile)), a 0.50x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.42β · 54% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.